Navigation Links
BioVex Reports Positive Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
Date:6/1/2008

CHICAGO, June 1 /PRNewswire/ -- BioVex Inc, a biotechnology company developing clinical stage treatments for cancer and the prevention of infectious disease, today announced positive results from its Phase II clinical trial of OncoVEX GM-CSF, an oncolytic for the treatment of advanced metastatic melanoma, at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL.

Clinical Trial Details

Phase II Trial Design: The Phase II trial was conducted at seven U.S. clinical centers, including the Mary Crowley Cancer Research Center, Dallas, TX; Columbia University, New York, NY; The Hubert H. Humphrey Cancer Center, Minneapolis, MN; and the University of California San Diego, San Diego, CA. Fifty patients with inoperable Stage IIIc/IV melanoma were enrolled. Patients were given OncoVEX GM-CSF injections every two weeks for up to a year. The trial was designed to measure overall objective response, which is defined as a complete response, where disease is completely eliminated, or partial response, where there is a >30% reduction in disease burden. The target efficacy endpoint detailed in the Phase II protocol and agreed with the FDA was to achieve two objective responses or stable disease >2 months.

Phase II results: Among 43 patients currently evaluable of the 50 patients enrolled, tumors injected with OncoVEX GM-CSF routinely responded, often with local complete responses or palliative benefit. With regard to systemic overall responses required for treatment success (including tumor responses at sites distant from injected tumors), six patients showed complete clinical responses; five of which are ongoing at between four and 27 months post first injection. The sixth complete response patient presented with a new lesion 15 months after initiating therapy. A further six patients achieved a partial response, five of which are ongoing 7-13 months post first injection and two of which have no disease after surgical r
'/>"/>

SOURCE BioVex Inc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
2. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
3. Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO
4. Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives
5. Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
6. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
7. DATATRAK International Reports First Quarter Results for 2008
8. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
9. Neurocrine Biosciences Reports First Quarter 2008 Results
10. Phosphagenics Reports Positive Pre-clinical Results for Targeted Delivery of Lidocaine
11. Cardica Reports Positive Top-Line Results and Submits 510(k) for PAS-Port(R) Proximal Anastomosis System in Cardiac Bypass Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... CORALVILLE, Iowa , Sept. 23, 2014 /PRNewswire/ ... in the discovery and development of proprietary new ... received a No Objection Letter (NOL) from Health ... Canada for its lead product candidate ... hydrocodone prodrug in development for acute moderate to ...
(Date:9/23/2014)... 23, 2014 According to ... Product (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave), Application ... - Global Forecasts to 2019", published by MarketsandMarkets, studies ... period of 2014 to 2019. The market is ... CAGR of 9.6% from 2014 to 2019. ...
(Date:9/23/2014)... 23, 2014  Medela announced today that it has ... assigning Medela as the exclusive distributor of the ABC ... Medela Enteral Feeding Pump. Through this agreement, Medela will ... and healthcare professionals by offering a comprehensive set of ... Pump is integral to the delivery of human milk ...
Breaking Medicine Technology:KemPharm Receives Health Canada Approval to Begin KP201 Clinical Trials in Canada 2KemPharm Receives Health Canada Approval to Begin KP201 Clinical Trials in Canada 3Ablation Technologies Market Worth $3.81 Billion by 2019 2Ablation Technologies Market Worth $3.81 Billion by 2019 3Ablation Technologies Market Worth $3.81 Billion by 2019 4Medela Enters Exclusive Enteral Feeding Pump Agreement with Atlanta Biomedical Company 2
... 14, 2011 Novocure, a commercial stage private ... former senior OSI Pharmaceuticals executives to its Global ... for bringing the company,s new tumor treating fields ... Peter M. Melnyk has joined Novocure as ...
...  SRI International has been awarded a contract worth up ... Institute of Allergy and Infectious Diseases (NIAID), part of ... will allow SRI to continue a program that supports ... the translation of basic research into clinical applications. Since ...
Cached Medicine Technology:Novocure Adds Three Senior Oncology Executives to its Global Management Team 2Novocure Adds Three Senior Oncology Executives to its Global Management Team 3Novocure Adds Three Senior Oncology Executives to its Global Management Team 4SRI International Awarded Contract Worth Up to $100M From National Institute of Allergy and Infectious Diseases 2SRI International Awarded Contract Worth Up to $100M From National Institute of Allergy and Infectious Diseases 3
(Date:9/23/2014)... Genomic medicine is rapidly developing, bringing with its ... and optimize prevention and treatment interventions. Genetic ... immunodeficiency virus (HIV) and hepatitis c virus (HPC), ... be used to screen for an individual,s susceptibility ... treatments for addiction. , While there appear to ...
(Date:9/23/2014)... 23, 2014 What information do ... National Quality Forum (NQF) released a report ( ... and an infographic ( http://bit.ly/1tX3lzA ) resulting from ... healthcare, how patients define affordability, and what information ... the best possible healthcare at the lowest possible ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 What: ... Manhattan’s Upper West Side that embodies the inclusion ... Eden: Christians, Scripture and the Ecological Crisis, a ... B. Rhodes Professor Emerita of Old Testament at ... for ancient wisdom that lends insight into current ...
(Date:9/23/2014)... 23, 2014 (HealthDay News) -- The number of ... drugs is growing, so doctors need to be ... Drug Administration warned Tuesday. In a statement, ... that it has launched a program to educate ... about proper drug purchasing procedures. The program aims ...
(Date:9/23/2014)... obese as teenagers could grow up to earn up ... weight. So says Petter Lundborg of Lund University, Paul ... University and Lund University, all in Sweden. The team ... the United States, and the results are published in ... analyzed large-scale data of 145,193 Swedish-born brothers who enlisted ...
Breaking Medicine News(10 mins):Health News:NYU-Mount Sinai Beth Israel study explores drug users' opinions on genetic testing 2Health News:Finding Affordable Care: Asking the Right Question is Key 2Health News:Inhabiting Eden: Christians, Scripture, and the Ecological Crisis – Public Lecture to Discuss Faith-Based Environmentalism 2Health News:Note to young men: Fat doesn't pay 2
... A path breaking research published today seems to have ... be able to manufacture their own sperms. Lesbian couples// ... ,Researchers have applied for permission to generate synthetic ... this move will be ethical is a question that ...
... the key to not only stopping heart attacks in ... Researchers at Mount Sinai School of Medicine have shown ... novel contrast agent know as N1177 can detect dangerous, ... findings may help physicians diagnosis a heart attack before ...
... Alirajpur in Jhabua district, beat his wife to death. Reason? ... another young man killed his brother with an arrow when ... owned by him. ,Often the reasons for murders ... entering the neighbour's territory or someone's refusal to lend a ...
... - If you are obese, blame it on your gene. A ... called FTO portray mutation in both their copies, then such people ... people who possess normal copies of the gene. ,Researchers ... of what is happening, this research could give us an answer ...
... M.D., director of the Yale Child Study Center and ... discuss the expansion of the Center’s specialty clinical services ... at Greenwich Library, 101 W. Putnam Ave., Greenwich. ... new clinical services, which will also benefit clients from ...
... Northeastern states in the US are stepping up their efforts ... mercury emissions.// ,Throughout the Northeast, mercury contamination ... that occurs naturally. , It is released ... generating plants. ,Smokestack emissions drift across state ...
Cached Medicine News:Health News:CT Imaging With Novel Contrast Agent May Predict Heart Attack in Waiting 2Health News:Efforts Underway to Fight Alcoholism Among Tribals 2Health News:Efforts Underway to Fight Alcoholism Among Tribals 3Health News:Efforts Underway to Fight Alcoholism Among Tribals 4Health News:US States Get Ready to Fight Mercury Pollution 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: